HPES | Jotup

Expert Panel Upgrades Home Price Growth Outlook, Cites Supply Constraints and Lower Mortgage Rates

Retrieved on:

Thursday, February 29, 2024

OTCQB, Fannie Mae, HPES, Calendar, ESR Group, Economy, FNMA, ESR, Housing, Partnership

WASHINGTON, Feb. 29, 2024 /PRNewswire/ -- A panel of housing experts expects annual national home price growth of 3.8% in 2024 and 3.4% in 2025, according to the Q1 2024 Fannie Mae (OTCQB: FNMA) Home Price Expectations Survey (HPES), produced in partnership with Pulsenomics, LLC. The HPES polls over 100 experts across the housing and mortgage industry and academia for forecasts of national home price percentage changes in each of the coming five calendar years, as measured by the Fannie Mae Home Price Index (FNM-HPI).

Key Points:

The panel's latest estimates of national home price growth are higher than last quarter's expectations of 2.4% for 2024 and 2.7% for 2025.
Additionally, an increased share of panelists indicated higher upside risk to their home price forecasts – 41 percent in Q1 2024 compared to 26 percent in Q4 2023 – with a majority citing ongoing housing supply constraints and lower mortgage rates as the basis for that belief.
The panel also projects a median 30-year fixed mortgage rate of 6% by the end of 2024.
"If mortgage rates move toward the panel-predicted six percent median rate by the end of 2024, we would expect this to be supportive of continued home price growth, particularly given the persistent supply-side challenges facing the housing market."

Expert Panel Sees Home Prices Rising 2.4% in 2024 and 2.7% in 2025, New Fannie Mae Survey Shows

Retrieved on:

Monday, December 11, 2023

Pressure, OTCQB, Economy, Calendar, Artificial intelligence, Fannie Mae, ESR Group, FNMA, Partnership, Housing, Growth, Environment, HPES, ESR, Real estate

WASHINGTON, Dec. 11, 2023 /PRNewswire/ -- A panel of housing experts expects annual national home price growth of 2.4% in 2024 and 2.7% in 2025, according to the Q4 2023 Fannie Mae (OTCQB: FNMA) Home Price Expectations Survey (HPES), produced in partnership with Pulsenomics, LLC. The HPES polls over 100 experts across the housing and mortgage industry and academia for forecasts of national home price percentage changes in each of the coming five calendar years, as measured by the Fannie Mae Home Price Index (FNM-HPI). On average, the panel anticipates home price growth to clock in at 5.9% in 2023, to be followed by slower growth in 2024 and 2025 of 2.4 percent and 2.7 percent, respectively. Complete results of the Q4 2023 survey can be found here.

Key Points:

On average, the panel anticipates home price growth to clock in at 5.9% in 2023, to be followed by slower growth in 2024 and 2025 of 2.4 percent and 2.7 percent, respectively.
Complete results of the Q4 2023 survey can be found here .
The average respondent expects the 30-year fixed rate mortgage rate to eventually settle to an average of approximately 5.7%.
To receive e-mail updates regarding future HPES updates and other economic and housing market research from Fannie Mae's Economic & Strategic Research Group, please click here .

Fannie Mae Announces Partnership with Pulsenomics to Produce Home Price Expectations Survey

Retrieved on:

Tuesday, October 3, 2023

Partnership, Housing, Fannie Mae, Life, Economy, ESR, Calendar, ESR Group, OTCQB, Research, Home, FNMA, HPES, Management

WASHINGTON, Oct. 3, 2023 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) announced today a partnership with Pulsenomics LLC, an independent research and consulting firm, to produce the quarterly Home Price Expectations Survey (HPES) beginning this month. The HPES polls over 100 housing experts across the industry and academia for forecasts of national home price percentage changes in each of the coming five calendar years. On a quarterly basis, Fannie Mae will publish the survey results, including respondent feedback on topical questions designed to help inform the broader housing industry.

Key Points:

WASHINGTON, Oct. 3, 2023 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) announced today a partnership with Pulsenomics LLC, an independent research and consulting firm, to produce the quarterly Home Price Expectations Survey (HPES) beginning this month.
On a quarterly basis, Fannie Mae will publish the survey results, including respondent feedback on topical questions designed to help inform the broader housing industry.
"We're excited to partner with Pulsenomics to add the Home Price Expectations Survey to our suite of economic and housing research products, particularly given our ESR Group's ongoing participation as a respondent," said Doug Duncan, Fannie Mae Senior Vice President and Chief Economist.
"For Pulsenomics, this partnership represents the opening of an exciting new chapter in the life of our nearly fifteen-year survey research effort," said Terry Loebs, founder of Pulsenomics.

Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting

Retrieved on:

Monday, October 2, 2023

COPENHAGEN, Denmark, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) presented a poster with results of a sub-analysis of its Phase 3 PaTHway clinical trial data during the recent American Thyroid Association (ATA) annual meeting, showing that 81% of adults with chronic post-surgical hypoparathyroidism (n = 70) treated with TransCon PTH (palopegteriparatide) achieved independence from conventional calcium and active vitamin D therapy while maintaining normal serum calcium levels during the 26-week blinded portion of the trial, compared to 6% taking placebo. The results were comparable to those from the overall PaTHway Trial population (N = 82), which demonstrated consistency in improved outcomes with TransCon PTH treatment compared to conventional therapy across disease etiologies.

Key Points:

TransCon PTH is an investigational prodrug with sustained release of active parathyroid hormone (PTH [1-34]) administered once daily.
TransCon PTH (palopegteriparatide) has received a positive CHMP opinion recommending approval in the European Union and is in development in the United States, and Japan for the treatment of adults with hypoparathyroidism.
A total of 84 patients were randomized 3:1 to treatment with TransCon PTH (n = 63) or placebo (n = 21), both co-administered with conventional therapy.
Of those, the 70 with post-surgical hypoparathyroidism (52 TransCon PTH, 18 placebo) were included in the sub-analysis population.

Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May

Retrieved on:

Sunday, May 1, 2022

COPENHAGEN, Denmark, May 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will present clinical and research outcomes and host informational booths and events at four medical meetings during May. Topics will include new open-label extension data for children with growth hormone deficiency treated with TransCon hGH for 2.5 years; research findings showing comorbidities associated with adult growth hormone deficiency; and presentations of TransCon PTH Phase 2 patient-reported health, quality-of-life, and Week 84 data in adult hypoparathyroidism. Meetings in the United States will also showcase SKYTROFA® (lonapegsomatropin-tcgd), the Company’s FDA-approved once-weekly treatment for pediatric growth hormone deficiency.

Key Points:

Adult Population with Growth Hormone Deficiency
An analysis of the comorbidity burden in adult patients diagnosed with growth hormone deficiency (GHD) compared to non-GHD controls.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives.
Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma Group.